Neurology
Early Alzheimer's Disease
3
Pipeline Programs↗
23
Active Trials↗
22
Companies Involved↗
Early Alzheimer's Disease is an early-stage landscape with 3 programs across 22 companies. The most active players are Merck & Co., Eli Lilly, Novo Nordisk. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 21
Approved
No programs
Analysis
Modality Breakdown
2programs
Small molecule150%
Peptide150%
Modality classified for 75% of 4 pipeline programs.
Analysis
Trial Status
60
clinical trials
Completed21 · 35%
Terminated14 · 23%
Active, not recruiting12 · 20%
Recruiting9 · 15%
Not yet recruiting2 · 3%
Unknown status2 · 3%
Clinical Trials
Trial Activity
60 trials
Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06741553·120 enrolled
Stem Cell Therapy for Early Alzheimer's Disease
Recruiting·—·Phase 1/2·NCT06775964·12 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)